A new study being published in the upcoming issue of the journal Expert Opinion on Investigational Drugs, and published online ahead of print by the U.S. National Institute of Health, has found that cannabinoids may be a promising tool for the treatment of breast and prostate cancer.
According to the study’s abstract; “The aim of this review is to evaluate the promising chemotherapeutic utility of phytocannabinoids, endocannabinoids, and synthetic cannabinoids in breast and prostate cancer.”
In their evaluation, researchers found that; “Cannabinoids, in particular the non-psychoactive CBD, may be promising tools in combination therapy for breast and prostate cancer, due to their direct antitumor effects, their ability to improve the efficacy of conventional antitumor drugs and their usefulness as palliative treatment.”
Researchers do note that; “Nevertheless, deeper studies to fully establish the mechanisms responsible for their antitumour and pro-tumour properties and their formulation in efficient delivery systems remain to be established.”
The study, conducted at the Complutense University of Madrid in Spain, can be found by clicking here.